查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
骨髓發育不良症候群(MDS)治療藥的全球市場:成長，未來展望，競爭分析(2022年～2030年)
市場調查報告書
商品編碼
1180686

骨髓發育不良症候群(MDS)治療藥的全球市場:成長，未來展望，競爭分析(2022年～2030年)

Myelodysplastic Syndrome (MDS) Treatment Drugs Market - Growth, Future Prospects and Competitive Analysis, 2022 - 2030
出版日期: | 出版商: Acute Market Reports | 英文 118 Pages | 商品交期: 最快1-2個工作天內

價格

全球骨髓發育不良症候群 (MDS) 治療市場受到骨髓發育不良症候群 (MDS) 患病率上升、醫療保健系統支出增加、治療研發投資增加以及理想管道的推動。由於線藥物的存在，預計將展示預測期內市場顯著增長。

本報告提供全球骨髓發育不良症候群(MDS)治療藥市場相關調查，提供競爭分析，與常量分析市場動態，藥物類別·各地區的市場分析，企業簡介等相關資訊。

目錄

第1章 序文

  • 報告的說明
  • 市場區隔
  • 調查手法

第2章 摘要整理

  • 市場概述:全球骨髓發育不良症候群(MDS)治療藥市場
  • 全球骨髓發育不良症候群(MDS)治療藥市場:各類藥物(2021年，100萬美元)
  • 全球骨髓發育不良症候群(MDS)治療藥市場:各地區(2021年，100萬美元)
  • 富有魅力的投資提案:各地區，2021年

第3章 骨髓發育不良症候群(MDS)治療藥市場:競爭分析

  • 主要的骨髓發育不良症候群(MDS)治療藥的市場供應商的市場定位
  • 骨髓發育不良症候群(MDS)治療藥的市場供應商僱用的策略
  • 主要的產業策略
  • 階層分析:2021年VS2030年

第4章 骨髓發育不良症候群(MDS)治療藥市場:常量分析和市場動態

  • 簡介
  • 全球骨髓發育不良症候群(MDS)治療藥市場金額(2020年～2030年，100萬美元)
  • 市場動態
    • 推動市場要素
    • 阻礙市場要素
    • 主要課題
    • 主要的機會
  • 促進因素與阻礙因素的影響分析
  • Seesaw分析

第5章 骨髓發育不良症候群(MDS)治療藥市場:各類藥物(2020年～2030年，100萬美元)

  • 市場概要
  • 成長和收益分析:2021年VS2030年
  • 市場區隔
    • 定影劑甲基化劑
    • 免疫調節藥
    • 成長因素
    • 其他

第6章 北美的骨髓發育不良症候群(MDS)治療藥市場(2020年～2030年，100萬美元)

  • 市場概要
  • 各類藥物(2020年～2030年，100萬美元)
  • 各地區(2020年～2030年，100萬美元)
    • 北美

第7章 英國·歐洲聯盟的骨髓發育不良症候群(MDS)治療藥市場(2020年～2030年，100萬美元)

  • 市場概要
  • 各類藥物(2020年～2030年，100萬美元)
  • 各地區(2020年～2030年，100萬美元)
    • 英國·歐洲聯盟

第8章 亞太地區的骨髓發育不良症候群(MDS)治療藥市場(2020年～2030年，100萬美元)

  • 市場概要
  • 各類藥物(2020年～2030年，100萬美元)
  • 各地區(2020年～2030年，100萬美元)
    • 亞太地區

第9章 南美的骨髓發育不良症候群(MDS)治療藥市場(2020年～2030年，100萬美元)

  • 市場概要
  • 各類藥物(2020年～2030年，100萬美元)
  • 各地區(2020年～2030年，100萬美元)
    • 南美

第10章 中東·非洲的骨髓發育不良症候群(MDS)治療藥市場(2020年～2030年，100萬美元)

  • 市場概要
  • 各類藥物(2020年～2030年，100萬美元)
  • 各地區(2020年～2030年，100萬美元)
    • 中東·非洲

第11章 企業簡介

  • Bayer AG
  • Celator Pharmaceuticals(Jazz Pharmaceuticals plc.)
  • Celgene Corporation
  • Cell Therapeutics, Inc.
  • Daiichi Sankyo Company, Ltd.
  • Incyte Corporation
  • Janssen Biotech, Inc.
  • MedImmune, LLC(AstraZeneca)
  • Millennium Pharmaceuticals(Takeda Pharmaceutical)
  • Novartis AG
  • Onconova Therapeutics, Inc.
  • Pfizer, Inc.
  • Taiho Pharmaceutical(Otsuka Holdings)
  • 其他的主要企業
Product Code: 137932-08-22

Myelodysplastic syndrome (MDS) is type of cancer and it considered as group of blood and bone marrow disorders and involves production of abnormal and immature blood cells. It is anticipated that MDS treatment drugs market will show significant market growth over the forecast period due to rising prevalence of MDS, increase in spending in the healthcare system, growing investments in R&D for MDS treatment and strong presence of ideal pipeline drugs. Expected launch of late stage pipeline drugs such as JNJ-63935937, MLN-4924, NSC-39069 and rigosertib is anticipated to drive significant market growth over the forecast period 2022-2030.

The report titled "Myelodysplastic syndrome (MDS) Treatment Drugs Market - Growth, Future Prospects and Competitive Analysis, 2022-2030" covers in-depth data related to MDS treatment drugs market. The report covers overall analysis related to market segments based on drug class (hypomethylating agents, immunomodulatory drugs, growth factors and other) and different geographies.

Along with market size data, qualitative information tools are also provided in this report for in-depth analysis of the market situations. Market information such as drivers, challenges and opportunities about MDS treatment drugs are also included in report. To provide overall information regarding the expected launch of MDS therapeutics, pipeline analysis of late stage MDS treatment drugs is included in report. Competitive landscape of key manufactures and company profiles section are included in the report to provide general information regarding market players' position and growth. Furthermore, this report provides information such as merger and acquisitions among the key players in the MDS treatment drugs market.

MDS is characterized by production of immature blood cells that are unable to function properly and die earlier than normal blood cells. MDS treatment is preferably given for reducing the disease progression and managing symptoms of MDS. Although various forms of drugs are used in the treatment of MDS; currently, only three drugs are approved by the US- FDA, which include azacitidine, decitabine and lenalidomide. Higher number of unmet needs, strong presence of pipeline molecules, and growing pool of geriatric population are that prime factors influence the growth of MDS treatment drugs market. In the recent years, demand for hypomethylating agents has been the highest in the market due to its proven effectiveness in low as well as high risk MDS patients. Since 2006, no single drug has been approved by the US- FDA for the treatment of MDS. Expected launch of late stage pipeline molecules such as JNJ-63935937 (Janssen Biotech), MLN-4924 (Takeda Pharmaceutical), NSC 39069 (Medac) and rigosertib (Onconova Therapeutics) would drive lucrative market growth during forecast period 2022 to 2030.

In the base year 2021, North America held the largest market share for myelodysplastic syndrome treatment drugs and is anticipated to show dominance over the forecast period. United States is the largest market in North America. Some factors such as increase in prevalence of MDS, better early diagnosis rate, higher cost of treatment medication, high treatment awareness, favorable reimbursement policies by private organizations and government agencies are favoring the dominance of North America market. According to the American cancer society, in the United States, MDS occur at a rate of 4.8 cases for every 100,000 people; every year approximately 13,000 people are diagnose with MDS in United States. Swift adoption of novel medications and expected launch of late stage pipeline drugs such as JNJ-63935937, MLN-4924, NSC-39069 and rigosertib would further assists the MDS treatment drugs market in the United States. On the other hand, MDS treatment drugs market in Asia Pacific is set to tap significant growth during the forecast period due to growing number of geriatric population, increasing patient awareness and developing healthcare infrastructure.

Historical & Forecast Period

This study report represents analysis of each segment from 2020 to 2030 considering 2021 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2030.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Myelodysplastic Syndrome (MDS) Treatment Drugs market are as follows:

Research and development budgets of manufacturers and government spending

Revenues of key companies in the market segment

Number of end users and consumption volume, price and value.

Geographical revenues generate by countries considered in the report:

Micro and macro environment factors that are currently influencing the Myelodysplastic Syndrome (MDS) Treatment Drugs market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Market Segmentation

Drug Class

Hypomethylating Agents

Azacitidine

Decitabine

Immunomodulatory Drugs

Lenalidomide

Growth Factors

Epoetin Alfa

Darbepoetin Alfa

Filgrastim

Others

Cytarabine

Daunorubicin

Idarubicin

Topotecan

Fludarabine

Region Segment (2020-2030; US$ Million)

North America

U.S.

Canada

Rest of North America

UK and European Union

UK

Germany

Spain

Italy

France

Rest of Europe

Asia Pacific

China

Japan

India

Australia

South Korea

Rest of Asia Pacific

Latin America

Brazil

Mexico

Rest of Latin America

Middle East and Africa

GCC

Africa

Rest of Middle East and Africa

Global Impact of COVID-19 Segment (2020-2021; US$ Million )

Pre COVID-19 situation

Post COVID-19 situation

Key questions answered in this report:

What are the key micro and macro environmental factors that are impacting the growth of Myelodysplastic Syndrome (MDS) Treatment Drugs market?

What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?

Estimated forecast and market projections up to 2030.

Which segment accounts for the fastest CAGR during the forecast period?

Which market segment holds a larger market share and why?

Are low and middle-income economies investing in the Myelodysplastic Syndrome (MDS) Treatment Drugs market?

Which is the largest regional market for Myelodysplastic Syndrome (MDS) Treatment Drugs market?

What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?

Which are the key trends driving Myelodysplastic Syndrome (MDS) Treatment Drugs market growth?

Who are the key competitors and what are their key strategies to enhance their market presence in the Myelodysplastic Syndrome (MDS) Treatment Drugs market worldwide?

Table of Contents

1. Preface

  • 1.1. Report Description
    • 1.1.1. Purpose of the Report
    • 1.1.2. Target Audience
    • 1.1.3. Key Offerings
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
    • 1.3.1. Phase I - Secondary Research
    • 1.3.2. Phase II - Primary Research
    • 1.3.3. Phase III - Expert Panel Review
    • 1.3.4. Assumptions
    • 1.3.5. Approach Adopted

2. Executive Summary

  • 2.1. Market Snapshot: Global Myelodysplastic Syndrome (MDS) Treatment Drugs Market
  • 2.2. Global Myelodysplastic Syndrome (MDS) Treatment Drugs Market, By Drug Class, 2021 (US$ Million)
  • 2.3. Global Myelodysplastic Syndrome (MDS) Treatment Drugs Market, By Geography, 2021 (US$ Million)
  • 2.4. Attractive Investment Proposition by Geography, 2021

3. Myelodysplastic Syndrome (MDS) Treatment Drugs Market: Competitive Analysis

  • 3.1. Market Positioning of Key Myelodysplastic Syndrome (MDS) Treatment Drugs Market Vendors
  • 3.2. Strategies Adopted by Myelodysplastic Syndrome (MDS) Treatment Drugs Market Vendors
  • 3.3. Key Industry Strategies
  • 3.4. Tier Analysis 2021 Versus 2030

4. Myelodysplastic Syndrome (MDS) Treatment Drugs Market: Macro Analysis & Market Dynamics

  • 4.1. Introduction
  • 4.2. Global Myelodysplastic Syndrome (MDS) Treatment Drugs Market Value, 2020 - 2030, (US$ Million)
  • 4.3. Market Dynamics
    • 4.3.1. Market Drivers
    • 4.3.2. Market Restraints
    • 4.3.3. Key Challenges
    • 4.3.4. Key Opportunities
  • 4.4. Impact Analysis of Drivers and Restraints
  • 4.5. See-Saw Analysis

5. Myelodysplastic Syndrome (MDS) Treatment Drugs Market: By Drug Class, 2020-2030, USD (Million)

  • 5.1. Market Overview
  • 5.2. Growth & Revenue Analysis: 2021 Versus 2030
  • 5.3. Market Segmentation
    • 5.3.1. Hypomethylating Agents
      • 5.3.1.1. Azacitidine
      • 5.3.1.2. Decitabine
    • 5.3.2. Immunomodulatory Drugs
      • 5.3.2.1. Lenalidomide
    • 5.3.3. Growth Factors
      • 5.3.3.1. Epoetin Alfa
      • 5.3.3.2. Darbepoetin Alfa
      • 5.3.3.3. Filgrastim
    • 5.3.4. Others
      • 5.3.4.1. Cytarabine
      • 5.3.4.2. Daunorubicin
      • 5.3.4.3. Idarubicin
      • 5.3.4.4. Topotecan
      • 5.3.4.5. Fludarabine

6. North America Myelodysplastic Syndrome (MDS) Treatment Drugs Market, 2020-2030, USD (Million)

  • 6.1. Market Overview
  • 6.2. Myelodysplastic Syndrome (MDS) Treatment Drugs Market: By Drug Class, 2020-2030, USD (Million)
  • 6.3.Myelodysplastic Syndrome (MDS) Treatment Drugs Market: By Region, 2020-2030, USD (Million)
    • 6.3.1.North America
      • 6.3.1.1. U.S.
        • 6.3.1.1.1. Myelodysplastic Syndrome (MDS) Treatment Drugs Market: By Drug Class, 2020-2030, USD (Million)
      • 6.3.1.2. Canada
        • 6.3.1.2.1. Myelodysplastic Syndrome (MDS) Treatment Drugs Market: By Drug Class, 2020-2030, USD (Million)
      • 6.3.1.3. Rest of North America
        • 6.3.1.3.1. Myelodysplastic Syndrome (MDS) Treatment Drugs Market: By Drug Class, 2020-2030, USD (Million)

7. UK and European Union Myelodysplastic Syndrome (MDS) Treatment Drugs Market, 2020-2030, USD (Million)

  • 7.1. Market Overview
  • 7.2. Myelodysplastic Syndrome (MDS) Treatment Drugs Market: By Drug Class, 2020-2030, USD (Million)
  • 7.3.Myelodysplastic Syndrome (MDS) Treatment Drugs Market: By Region, 2020-2030, USD (Million)
    • 7.3.1.UK and European Union
      • 7.3.1.1. UK
        • 7.3.1.1.1. Myelodysplastic Syndrome (MDS) Treatment Drugs Market: By Drug Class, 2020-2030, USD (Million)
      • 7.3.1.2. Germany
        • 7.3.1.2.1. Myelodysplastic Syndrome (MDS) Treatment Drugs Market: By Drug Class, 2020-2030, USD (Million)
      • 7.3.1.3. Spain
        • 7.3.1.3.1. Myelodysplastic Syndrome (MDS) Treatment Drugs Market: By Drug Class, 2020-2030, USD (Million)
      • 7.3.1.4. Italy
        • 7.3.1.4.1. Myelodysplastic Syndrome (MDS) Treatment Drugs Market: By Drug Class, 2020-2030, USD (Million)
      • 7.3.1.5. France
        • 7.3.1.5.1. Myelodysplastic Syndrome (MDS) Treatment Drugs Market: By Drug Class, 2020-2030, USD (Million)
      • 7.3.1.6. Rest of Europe
        • 7.3.1.6.1. Myelodysplastic Syndrome (MDS) Treatment Drugs Market: By Drug Class, 2020-2030, USD (Million)

8. Asia Pacific Myelodysplastic Syndrome (MDS) Treatment Drugs Market, 2020-2030, USD (Million)

  • 8.1. Market Overview
  • 8.2. Myelodysplastic Syndrome (MDS) Treatment Drugs Market: By Drug Class, 2020-2030, USD (Million)
  • 8.3.Myelodysplastic Syndrome (MDS) Treatment Drugs Market: By Region, 2020-2030, USD (Million)
    • 8.3.1.Asia Pacific
      • 8.3.1.1. China
        • 8.3.1.1.1. Myelodysplastic Syndrome (MDS) Treatment Drugs Market: By Drug Class, 2020-2030, USD (Million)
      • 8.3.1.2. Japan
        • 8.3.1.2.1. Myelodysplastic Syndrome (MDS) Treatment Drugs Market: By Drug Class, 2020-2030, USD (Million)
      • 8.3.1.3. India
        • 8.3.1.3.1. Myelodysplastic Syndrome (MDS) Treatment Drugs Market: By Drug Class, 2020-2030, USD (Million)
      • 8.3.1.4. Australia
        • 8.3.1.4.1. Myelodysplastic Syndrome (MDS) Treatment Drugs Market: By Drug Class, 2020-2030, USD (Million)
      • 8.3.1.5. South Korea
        • 8.3.1.5.1. Myelodysplastic Syndrome (MDS) Treatment Drugs Market: By Drug Class, 2020-2030, USD (Million)
      • 8.3.1.6. Rest of Asia Pacific
        • 8.3.1.6.1. Myelodysplastic Syndrome (MDS) Treatment Drugs Market: By Drug Class, 2020-2030, USD (Million)

9. Latin America Myelodysplastic Syndrome (MDS) Treatment Drugs Market, 2020-2030, USD (Million)

  • 9.1. Market Overview
  • 9.2. Myelodysplastic Syndrome (MDS) Treatment Drugs Market: By Drug Class, 2020-2030, USD (Million)
  • 9.3.Myelodysplastic Syndrome (MDS) Treatment Drugs Market: By Region, 2020-2030, USD (Million)
    • 9.3.1.Latin America
      • 9.3.1.1. Brazil
        • 9.3.1.1.1. Myelodysplastic Syndrome (MDS) Treatment Drugs Market: By Drug Class, 2020-2030, USD (Million)
      • 9.3.1.2. Mexico
        • 9.3.1.2.1. Myelodysplastic Syndrome (MDS) Treatment Drugs Market: By Drug Class, 2020-2030, USD (Million)
      • 9.3.1.3. Rest of Latin America
        • 9.3.1.3.1. Myelodysplastic Syndrome (MDS) Treatment Drugs Market: By Drug Class, 2020-2030, USD (Million)

10. Middle East and Africa Myelodysplastic Syndrome (MDS) Treatment Drugs Market, 2020-2030, USD (Million)

  • 10.1. Market Overview
  • 10.2. Myelodysplastic Syndrome (MDS) Treatment Drugs Market: By Drug Class, 2020-2030, USD (Million)
  • 10.3.Myelodysplastic Syndrome (MDS) Treatment Drugs Market: By Region, 2020-2030, USD (Million)
    • 10.3.1.Middle East and Africa
      • 10.3.1.1. GCC
        • 10.3.1.1.1. Myelodysplastic Syndrome (MDS) Treatment Drugs Market: By Drug Class, 2020-2030, USD (Million)
      • 10.3.1.2. Africa
        • 10.3.1.2.1. Myelodysplastic Syndrome (MDS) Treatment Drugs Market: By Drug Class, 2020-2030, USD (Million)
      • 10.3.1.3. Rest of Middle East and Africa
        • 10.3.1.3.1. Myelodysplastic Syndrome (MDS) Treatment Drugs Market: By Drug Class, 2020-2030, USD (Million)

11. Company Profile

  • 11.1. Bayer AG
    • 11.1.1. Company Overview
    • 11.1.2. Financial Performance
    • 11.1.3. Product Portfolio
    • 11.1.4. Strategic Initiatives
  • 11.2. Celator Pharmaceuticals (Jazz Pharmaceuticals plc.)
    • 11.2.1. Company Overview
    • 11.2.2. Financial Performance
    • 11.2.3. Product Portfolio
    • 11.2.4. Strategic Initiatives
  • 11.3. Celgene Corporation
    • 11.3.1. Company Overview
    • 11.3.2. Financial Performance
    • 11.3.3. Product Portfolio
    • 11.3.4. Strategic Initiatives
  • 11.4. Cell Therapeutics, Inc.
    • 11.4.1. Company Overview
    • 11.4.2. Financial Performance
    • 11.4.3. Product Portfolio
    • 11.4.4. Strategic Initiatives
  • 11.5. Daiichi Sankyo Company, Ltd.
    • 11.5.1. Company Overview
    • 11.5.2. Financial Performance
    • 11.5.3. Product Portfolio
    • 11.5.4. Strategic Initiatives
  • 11.6. Incyte Corporation
    • 11.6.1. Company Overview
    • 11.6.2. Financial Performance
    • 11.6.3. Product Portfolio
    • 11.6.4. Strategic Initiatives
  • 11.7. Janssen Biotech, Inc.
    • 11.7.1. Company Overview
    • 11.7.2. Financial Performance
    • 11.7.3. Product Portfolio
    • 11.7.4. Strategic Initiatives
  • 11.8. MedImmune, LLC (AstraZeneca)
    • 11.8.1. Company Overview
    • 11.8.2. Financial Performance
    • 11.8.3. Product Portfolio
    • 11.8.4. Strategic Initiatives
  • 11.9. Millennium Pharmaceuticals (Takeda Pharmaceutical)
    • 11.9.1. Company Overview
    • 11.9.2. Financial Performance
    • 11.9.3. Product Portfolio
    • 11.9.4. Strategic Initiatives
  • 11.10. Novartis AG
    • 11.10.1. Company Overview
    • 11.10.2. Financial Performance
    • 11.10.3. Product Portfolio
    • 11.10.4. Strategic Initiatives
  • 11.11. Onconova Therapeutics, Inc.
    • 11.11.1. Company Overview
    • 11.11.2. Financial Performance
    • 11.11.3. Product Portfolio
    • 11.11.4. Strategic Initiatives
  • 11.12. Pfizer, Inc.
    • 11.12.1. Company Overview
    • 11.12.2. Financial Performance
    • 11.12.3. Product Portfolio
    • 11.12.4. Strategic Initiatives
  • 11.13. Taiho Pharmaceutical (Otsuka Holdings)
    • 11.13.1. Company Overview
    • 11.13.2. Financial Performance
    • 11.13.3. Product Portfolio
    • 11.13.4. Strategic Initiatives
  • 11.14. Other Notable Players
    • 11.14.1. Company Overview
    • 11.14.2. Financial Performance
    • 11.14.3. Product Portfolio
    • 11.14.4. Strategic Initiatives

List of Tables

  • TABLE 1 Global Myelodysplastic Syndrome (MDS) Treatment Drugs Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 2 Global Myelodysplastic Syndrome (MDS) Treatment Drugs Market By Hypomethylating Agents, 2020-2030, USD (Million)
  • TABLE 3 Global Myelodysplastic Syndrome (MDS) Treatment Drugs Market By Immunomodulatory Drugs, 2020-2030, USD (Million)
  • TABLE 4 Global Myelodysplastic Syndrome (MDS) Treatment Drugs Market By Growth Factors, 2020-2030, USD (Million)
  • TABLE 5 Global Myelodysplastic Syndrome (MDS) Treatment Drugs Market By Others, 2020-2030, USD (Million)
  • TABLE 6 North America Myelodysplastic Syndrome (MDS) Treatment Drugs Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 7 North America Myelodysplastic Syndrome (MDS) Treatment Drugs Market By Hypomethylating Agents, 2020-2030, USD (Million)
  • TABLE 8 North America Myelodysplastic Syndrome (MDS) Treatment Drugs Market By Immunomodulatory Drugs, 2020-2030, USD (Million)
  • TABLE 9 North America Myelodysplastic Syndrome (MDS) Treatment Drugs Market By Growth Factors, 2020-2030, USD (Million)
  • TABLE 10 North America Myelodysplastic Syndrome (MDS) Treatment Drugs Market By Others, 2020-2030, USD (Million)
  • TABLE 11 U.S. Myelodysplastic Syndrome (MDS) Treatment Drugs Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 12 U.S. Myelodysplastic Syndrome (MDS) Treatment Drugs Market By Hypomethylating Agents, 2020-2030, USD (Million)
  • TABLE 13 U.S. Myelodysplastic Syndrome (MDS) Treatment Drugs Market By Immunomodulatory Drugs, 2020-2030, USD (Million)
  • TABLE 14 U.S. Myelodysplastic Syndrome (MDS) Treatment Drugs Market By Growth Factors, 2020-2030, USD (Million)
  • TABLE 15 U.S. Myelodysplastic Syndrome (MDS) Treatment Drugs Market By Others, 2020-2030, USD (Million)
  • TABLE 16 Canada Myelodysplastic Syndrome (MDS) Treatment Drugs Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 17 Canada Myelodysplastic Syndrome (MDS) Treatment Drugs Market By Hypomethylating Agents, 2020-2030, USD (Million)
  • TABLE 18 Canada Myelodysplastic Syndrome (MDS) Treatment Drugs Market By Immunomodulatory Drugs, 2020-2030, USD (Million)
  • TABLE 19 Canada Myelodysplastic Syndrome (MDS) Treatment Drugs Market By Growth Factors, 2020-2030, USD (Million)
  • TABLE 20 Canada Myelodysplastic Syndrome (MDS) Treatment Drugs Market By Others, 2020-2030, USD (Million)
  • TABLE 21 Rest of North America Myelodysplastic Syndrome (MDS) Treatment Drugs Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 22 Rest of North America Myelodysplastic Syndrome (MDS) Treatment Drugs Market By Hypomethylating Agents, 2020-2030, USD (Million)
  • TABLE 23 Rest of North America Myelodysplastic Syndrome (MDS) Treatment Drugs Market By Immunomodulatory Drugs, 2020-2030, USD (Million)
  • TABLE 24 Rest of North America Myelodysplastic Syndrome (MDS) Treatment Drugs Market By Growth Factors, 2020-2030, USD (Million)
  • TABLE 25 Rest of North America Myelodysplastic Syndrome (MDS) Treatment Drugs Market By Others, 2020-2030, USD (Million)
  • TABLE 26 UK and European Union Myelodysplastic Syndrome (MDS) Treatment Drugs Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 27 UK and European Union Myelodysplastic Syndrome (MDS) Treatment Drugs Market By Hypomethylating Agents, 2020-2030, USD (Million)
  • TABLE 28 UK and European Union Myelodysplastic Syndrome (MDS) Treatment Drugs Market By Immunomodulatory Drugs, 2020-2030, USD (Million)
  • TABLE 29 UK and European Union Myelodysplastic Syndrome (MDS) Treatment Drugs Market By Growth Factors, 2020-2030, USD (Million)
  • TABLE 30 UK and European Union Myelodysplastic Syndrome (MDS) Treatment Drugs Market By Others, 2020-2030, USD (Million)
  • TABLE 31 UK Myelodysplastic Syndrome (MDS) Treatment Drugs Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 32 UK Myelodysplastic Syndrome (MDS) Treatment Drugs Market By Hypomethylating Agents, 2020-2030, USD (Million)
  • TABLE 33 UK Myelodysplastic Syndrome (MDS) Treatment Drugs Market By Immunomodulatory Drugs, 2020-2030, USD (Million)
  • TABLE 34 UK Myelodysplastic Syndrome (MDS) Treatment Drugs Market By Growth Factors, 2020-2030, USD (Million)
  • TABLE 35 UK Myelodysplastic Syndrome (MDS) Treatment Drugs Market By Others, 2020-2030, USD (Million)
  • TABLE 36 Germany Myelodysplastic Syndrome (MDS) Treatment Drugs Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 37 Germany Myelodysplastic Syndrome (MDS) Treatment Drugs Market By Hypomethylating Agents, 2020-2030, USD (Million)
  • TABLE 38 Germany Myelodysplastic Syndrome (MDS) Treatment Drugs Market By Immunomodulatory Drugs, 2020-2030, USD (Million)
  • TABLE 39 Germany Myelodysplastic Syndrome (MDS) Treatment Drugs Market By Growth Factors, 2020-2030, USD (Million)
  • TABLE 40 Germany Myelodysplastic Syndrome (MDS) Treatment Drugs Market By Others, 2020-2030, USD (Million)
  • TABLE 41 Spain Myelodysplastic Syndrome (MDS) Treatment Drugs Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 42 Spain Myelodysplastic Syndrome (MDS) Treatment Drugs Market By Hypomethylating Agents, 2020-2030, USD (Million)
  • TABLE 43 Spain Myelodysplastic Syndrome (MDS) Treatment Drugs Market By Immunomodulatory Drugs, 2020-2030, USD (Million)
  • TABLE 44 Spain Myelodysplastic Syndrome (MDS) Treatment Drugs Market By Growth Factors, 2020-2030, USD (Million)
  • TABLE 45 Spain Myelodysplastic Syndrome (MDS) Treatment Drugs Market By Others, 2020-2030, USD (Million)
  • TABLE 46 Italy Myelodysplastic Syndrome (MDS) Treatment Drugs Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 47 Italy Myelodysplastic Syndrome (MDS) Treatment Drugs Market By Hypomethylating Agents, 2020-2030, USD (Million)
  • TABLE 48 Italy Myelodysplastic Syndrome (MDS) Treatment Drugs Market By Immunomodulatory Drugs, 2020-2030, USD (Million)
  • TABLE 49 Italy Myelodysplastic Syndrome (MDS) Treatment Drugs Market By Growth Factors, 2020-2030, USD (Million)
  • TABLE 50 Italy Myelodysplastic Syndrome (MDS) Treatment Drugs Market By Others, 2020-2030, USD (Million)
  • TABLE 51 France Myelodysplastic Syndrome (MDS) Treatment Drugs Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 52 France Myelodysplastic Syndrome (MDS) Treatment Drugs Market By Hypomethylating Agents, 2020-2030, USD (Million)
  • TABLE 53 France Myelodysplastic Syndrome (MDS) Treatment Drugs Market By Immunomodulatory Drugs, 2020-2030, USD (Million)
  • TABLE 54 France Myelodysplastic Syndrome (MDS) Treatment Drugs Market By Growth Factors, 2020-2030, USD (Million)
  • TABLE 55 France Myelodysplastic Syndrome (MDS) Treatment Drugs Market By Others, 2020-2030, USD (Million)
  • TABLE 56 Rest of Europe Myelodysplastic Syndrome (MDS) Treatment Drugs Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 57 Rest of Europe Myelodysplastic Syndrome (MDS) Treatment Drugs Market By Hypomethylating Agents, 2020-2030, USD (Million)
  • TABLE 58 Rest of Europe Myelodysplastic Syndrome (MDS) Treatment Drugs Market By Immunomodulatory Drugs, 2020-2030, USD (Million)
  • TABLE 59 Rest of Europe Myelodysplastic Syndrome (MDS) Treatment Drugs Market By Growth Factors, 2020-2030, USD (Million)
  • TABLE 60 Rest of Europe Myelodysplastic Syndrome (MDS) Treatment Drugs Market By Others, 2020-2030, USD (Million)
  • TABLE 61 Asia Myelodysplastic Syndrome (MDS) Treatment Drugs Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 62 Asia Myelodysplastic Syndrome (MDS) Treatment Drugs Market By Hypomethylating Agents, 2020-2030, USD (Million)
  • TABLE 63 Asia Myelodysplastic Syndrome (MDS) Treatment Drugs Market By Immunomodulatory Drugs, 2020-2030, USD (Million)
  • TABLE 64 Asia Myelodysplastic Syndrome (MDS) Treatment Drugs Market By Growth Factors, 2020-2030, USD (Million)
  • TABLE 65 Asia Myelodysplastic Syndrome (MDS) Treatment Drugs Market By Others, 2020-2030, USD (Million)
  • TABLE 66 China Myelodysplastic Syndrome (MDS) Treatment Drugs Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 67 China Myelodysplastic Syndrome (MDS) Treatment Drugs Market By Hypomethylating Agents, 2020-2030, USD (Million)
  • TABLE 68 China Myelodysplastic Syndrome (MDS) Treatment Drugs Market By Immunomodulatory Drugs, 2020-2030, USD (Million)
  • TABLE 69 China Myelodysplastic Syndrome (MDS) Treatment Drugs Market By Growth Factors, 2020-2030, USD (Million)
  • TABLE 70 China Myelodysplastic Syndrome (MDS) Treatment Drugs Market By Others, 2020-2030, USD (Million)
  • TABLE 71 Japan Myelodysplastic Syndrome (MDS) Treatment Drugs Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 72 Japan Myelodysplastic Syndrome (MDS) Treatment Drugs Market By Hypomethylating Agents, 2020-2030, USD (Million)
  • TABLE 73 Japan Myelodysplastic Syndrome (MDS) Treatment Drugs Market By Immunomodulatory Drugs, 2020-2030, USD (Million)
  • TABLE 74 Japan Myelodysplastic Syndrome (MDS) Treatment Drugs Market By Growth Factors, 2020-2030, USD (Million)
  • TABLE 75 Japan Myelodysplastic Syndrome (MDS) Treatment Drugs Market By Others, 2020-2030, USD (Million)
  • TABLE 76 India Myelodysplastic Syndrome (MDS) Treatment Drugs Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 77 India Myelodysplastic Syndrome (MDS) Treatment Drugs Market By Hypomethylating Agents, 2020-2030, USD (Million)
  • TABLE 78 India Myelodysplastic Syndrome (MDS) Treatment Drugs Market By Immunomodulatory Drugs, 2020-2030, USD (Million)
  • TABLE 79 India Myelodysplastic Syndrome (MDS) Treatment Drugs Market By Growth Factors, 2020-2030, USD (Million)
  • TABLE 80 India Myelodysplastic Syndrome (MDS) Treatment Drugs Market By Others, 2020-2030, USD (Million)
  • TABLE 81 Australia Myelodysplastic Syndrome (MDS) Treatment Drugs Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 82 Australia Myelodysplastic Syndrome (MDS) Treatment Drugs Market By Hypomethylating Agents, 2020-2030, USD (Million)
  • TABLE 83 Australia Myelodysplastic Syndrome (MDS) Treatment Drugs Market By Immunomodulatory Drugs, 2020-2030, USD (Million)
  • TABLE 84 Australia Myelodysplastic Syndrome (MDS) Treatment Drugs Market By Growth Factors, 2020-2030, USD (Million)
  • TABLE 85 Australia Myelodysplastic Syndrome (MDS) Treatment Drugs Market By Others, 2020-2030, USD (Million)
  • TABLE 86 South Korea Myelodysplastic Syndrome (MDS) Treatment Drugs Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 87 South Korea Myelodysplastic Syndrome (MDS) Treatment Drugs Market By Hypomethylating Agents, 2020-2030, USD (Million)
  • TABLE 88 South Korea Myelodysplastic Syndrome (MDS) Treatment Drugs Market By Immunomodulatory Drugs, 2020-2030, USD (Million)
  • TABLE 89 South Korea Myelodysplastic Syndrome (MDS) Treatment Drugs Market By Growth Factors, 2020-2030, USD (Million)
  • TABLE 90 South Korea Myelodysplastic Syndrome (MDS) Treatment Drugs Market By Others, 2020-2030, USD (Million)
  • TABLE 91 Latin America Myelodysplastic Syndrome (MDS) Treatment Drugs Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 92 Latin America Myelodysplastic Syndrome (MDS) Treatment Drugs Market By Hypomethylating Agents, 2020-2030, USD (Million)
  • TABLE 93 Latin America Myelodysplastic Syndrome (MDS) Treatment Drugs Market By Immunomodulatory Drugs, 2020-2030, USD (Million)
  • TABLE 94 Latin America Myelodysplastic Syndrome (MDS) Treatment Drugs Market By Growth Factors, 2020-2030, USD (Million)
  • TABLE 95 Latin America Myelodysplastic Syndrome (MDS) Treatment Drugs Market By Others, 2020-2030, USD (Million)
  • TABLE 96 Brazil Myelodysplastic Syndrome (MDS) Treatment Drugs Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 97 Brazil Myelodysplastic Syndrome (MDS) Treatment Drugs Market By Hypomethylating Agents, 2020-2030, USD (Million)
  • TABLE 98 Brazil Myelodysplastic Syndrome (MDS) Treatment Drugs Market By Immunomodulatory Drugs, 2020-2030, USD (Million)
  • TABLE 99 Brazil Myelodysplastic Syndrome (MDS) Treatment Drugs Market By Growth Factors, 2020-2030, USD (Million)
  • TABLE 100 Brazil Myelodysplastic Syndrome (MDS) Treatment Drugs Market By Others, 2020-2030, USD (Million)
  • TABLE 101 Mexico Myelodysplastic Syndrome (MDS) Treatment Drugs Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 102 Mexico Myelodysplastic Syndrome (MDS) Treatment Drugs Market By Hypomethylating Agents, 2020-2030, USD (Million)
  • TABLE 103 Mexico Myelodysplastic Syndrome (MDS) Treatment Drugs Market By Immunomodulatory Drugs, 2020-2030, USD (Million)
  • TABLE 104 Mexico Myelodysplastic Syndrome (MDS) Treatment Drugs Market By Growth Factors, 2020-2030, USD (Million)
  • TABLE 105 Mexico Myelodysplastic Syndrome (MDS) Treatment Drugs Market By Others, 2020-2030, USD (Million)
  • TABLE 106 Rest of Latin America Myelodysplastic Syndrome (MDS) Treatment Drugs Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 107 Rest of Latin America Myelodysplastic Syndrome (MDS) Treatment Drugs Market By Hypomethylating Agents, 2020-2030, USD (Million)
  • TABLE 108 Rest of Latin America Myelodysplastic Syndrome (MDS) Treatment Drugs Market By Immunomodulatory Drugs, 2020-2030, USD (Million)
  • TABLE 109 Rest of Latin America Myelodysplastic Syndrome (MDS) Treatment Drugs Market By Growth Factors, 2020-2030, USD (Million)
  • TABLE 110 Rest of Latin America Myelodysplastic Syndrome (MDS) Treatment Drugs Market By Others, 2020-2030, USD (Million)
  • TABLE 111 Middle East and Africa Myelodysplastic Syndrome (MDS) Treatment Drugs Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 112 Middle East and Africa Myelodysplastic Syndrome (MDS) Treatment Drugs Market By Hypomethylating Agents, 2020-2030, USD (Million)
  • TABLE 113 Middle East and Africa Myelodysplastic Syndrome (MDS) Treatment Drugs Market By Immunomodulatory Drugs, 2020-2030, USD (Million)
  • TABLE 114 Middle East and Africa Myelodysplastic Syndrome (MDS) Treatment Drugs Market By Growth Factors, 2020-2030, USD (Million)
  • TABLE 115 Middle East and Africa Myelodysplastic Syndrome (MDS) Treatment Drugs Market By Others, 2020-2030, USD (Million)
  • TABLE 116 GCC Myelodysplastic Syndrome (MDS) Treatment Drugs Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 117 GCC Myelodysplastic Syndrome (MDS) Treatment Drugs Market By Hypomethylating Agents, 2020-2030, USD (Million)
  • TABLE 118 GCC Myelodysplastic Syndrome (MDS) Treatment Drugs Market By Immunomodulatory Drugs, 2020-2030, USD (Million)
  • TABLE 119 GCC Myelodysplastic Syndrome (MDS) Treatment Drugs Market By Growth Factors, 2020-2030, USD (Million)
  • TABLE 120 GCC Myelodysplastic Syndrome (MDS) Treatment Drugs Market By Others, 2020-2030, USD (Million)
  • TABLE 121 Africa Myelodysplastic Syndrome (MDS) Treatment Drugs Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 122 Africa Myelodysplastic Syndrome (MDS) Treatment Drugs Market By Hypomethylating Agents, 2020-2030, USD (Million)
  • TABLE 123 Africa Myelodysplastic Syndrome (MDS) Treatment Drugs Market By Immunomodulatory Drugs, 2020-2030, USD (Million)
  • TABLE 124 Africa Myelodysplastic Syndrome (MDS) Treatment Drugs Market By Growth Factors, 2020-2030, USD (Million)
  • TABLE 125 Africa Myelodysplastic Syndrome (MDS) Treatment Drugs Market By Others, 2020-2030, USD (Million)
  • TABLE 126 Rest of Middle East and Africa Myelodysplastic Syndrome (MDS) Treatment Drugs Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 127 Rest of Middle East and Africa Myelodysplastic Syndrome (MDS) Treatment Drugs Market By Hypomethylating Agents, 2020-2030, USD (Million)
  • TABLE 128 Rest of Middle East and Africa Myelodysplastic Syndrome (MDS) Treatment Drugs Market By Immunomodulatory Drugs, 2020-2030, USD (Million)
  • TABLE 129 Rest of Middle East and Africa Myelodysplastic Syndrome (MDS) Treatment Drugs Market By Growth Factors, 2020-2030, USD (Million)
  • TABLE 130 Rest of Middle East and Africa Myelodysplastic Syndrome (MDS) Treatment Drugs Market By Others, 2020-2030, USD (Million)

List of Figures

  • FIG. 1 Global Myelodysplastic Syndrome (MDS) Treatment Drugs Market: Market Coverage
  • FIG. 2 Research Methodology and Data Sources
  • FIG. 3 Market Size Estimation - Top Down & Bottom-Up Approach
  • FIG. 4 Global Myelodysplastic Syndrome (MDS) Treatment Drugs Market: Quality Assurance
  • FIG. 5 Global Myelodysplastic Syndrome (MDS) Treatment Drugs Market, By Drug Class, 2021
  • FIG. 6 Global Myelodysplastic Syndrome (MDS) Treatment Drugs Market, By Geography, 2021
  • FIG. 7 Market Geographical Opportunity Matrix - Global Myelodysplastic Syndrome (MDS) Treatment Drugs Market, 2021
  • FIG. 8 Market Positioning of Key Myelodysplastic Syndrome (MDS) Treatment Drugs Market Players, 2021
  • FIG. 9 Global Myelodysplastic Syndrome (MDS) Treatment Drugs Market - Tier Analysis - Percentage of Revenues by Tier Level, 2021 Versus 2030
  • FIG. 10 Global Myelodysplastic Syndrome (MDS) Treatment Drugs Market, By Drug Class, 2021 Vs 2030, %
  • FIG. 11 U.S. Myelodysplastic Syndrome (MDS) Treatment Drugs Market (US$ Million), 2020 - 2030
  • FIG. 12 Canada Myelodysplastic Syndrome (MDS) Treatment Drugs Market (US$ Million), 2020 - 2030
  • FIG. 13 Rest of North America Myelodysplastic Syndrome (MDS) Treatment Drugs Market (US$ Million), 2020 - 2030
  • FIG. 14 UK Myelodysplastic Syndrome (MDS) Treatment Drugs Market (US$ Million), 2020 - 2030
  • FIG. 15 Germany Myelodysplastic Syndrome (MDS) Treatment Drugs Market (US$ Million), 2020 - 2030
  • FIG. 16 Spain Myelodysplastic Syndrome (MDS) Treatment Drugs Market (US$ Million), 2020 - 2030
  • FIG. 17 Italy Myelodysplastic Syndrome (MDS) Treatment Drugs Market (US$ Million), 2020 - 2030
  • FIG. 18 France Myelodysplastic Syndrome (MDS) Treatment Drugs Market (US$ Million), 2020 - 2030
  • FIG. 19 Rest of Europe Myelodysplastic Syndrome (MDS) Treatment Drugs Market (US$ Million), 2020 - 2030
  • FIG. 20 China Myelodysplastic Syndrome (MDS) Treatment Drugs Market (US$ Million), 2020 - 2030
  • FIG. 21 Japan Myelodysplastic Syndrome (MDS) Treatment Drugs Market (US$ Million), 2020 - 2030
  • FIG. 22 India Myelodysplastic Syndrome (MDS) Treatment Drugs Market (US$ Million), 2020 - 2030
  • FIG. 23 Australia Myelodysplastic Syndrome (MDS) Treatment Drugs Market (US$ Million), 2020 - 2030
  • FIG. 24 South Korea Myelodysplastic Syndrome (MDS) Treatment Drugs Market (US$ Million), 2020 - 2030
  • FIG. 25 Rest of Asia Myelodysplastic Syndrome (MDS) Treatment Drugs Market (US$ Million), 2020 - 2030
  • FIG. 26 Brazil Myelodysplastic Syndrome (MDS) Treatment Drugs Market (US$ Million), 2020 - 2030
  • FIG. 27 Mexico Myelodysplastic Syndrome (MDS) Treatment Drugs Market (US$ Million), 2020 - 2030
  • FIG. 28 Rest of Latin America Myelodysplastic Syndrome (MDS) Treatment Drugs Market (US$ Million), 2020 - 2030
  • FIG. 29 GCC Myelodysplastic Syndrome (MDS) Treatment Drugs Market (US$ Million), 2020 - 2030
  • FIG. 30 Africa Myelodysplastic Syndrome (MDS) Treatment Drugs Market (US$ Million), 2020 - 2030
  • FIG. 31 Rest of Middle East and Africa Myelodysplastic Syndrome (MDS) Treatment Drugs Market (US$ Million), 2020 - 2030